Effect of spironolactone on K+ homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients

Kidney International

Volumn 66, Issue 4, 2004, Pages 1647-1653

  Michea, Luis ^a   Vukusich, Antonio ^b   González, Magdalena ^b   Zehnder, Carlos ^b   Marusic, Elisa T ^b  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

^b NONE

Author keywords

Aldosterone; Cardiovascular; Hyperkalemia; Renal disease; Sodium channel

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; CARBOHYDRATE; MESSENGER RNA; POTASSIUM; SODIUM CHANNEL; SPIRONOLACTONE;

ADOLESCENT; ADULT; AGED; ALPHA CHAIN; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; ENSURE PLUS; FEMALE; HEART DISEASE; HEMODIALYSIS; HOMEOSTASIS; HUMAN; HYPERKALEMIA; LYMPHOCYTE; MALE; MONONUCLEAR CELL; POTASSIUM BALANCE; PRIORITY JOURNAL;

EID: 4644313400     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00931.x     Document Type: Article

References (53)

1. ROCHA R, FUNDER JW: The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 970:89-100, 2002
2. BRILLA CG, WEBER KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 26:671-677, 1992
3. NGARMUKOS C, GREKIN RJ: Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab 281:E1122-1127, 2001
4. YOUNG M, HEAD J, FUNDER JW: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 269:E657-E662, 1995
5. MACFADYEN RJ, BARR CS, STRUTHERS AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35:30-34, 1997
6. UNITED STATES RENAL DATA SYSTEM: Annual data report: Part VI. Causes of death. Am J Kidney Dis 34:S87-S94, 1999
7. HERZOG CA, MA JZ, COLLINS AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339:799-805, 1998
8. SILBERG JS, BARRE PE, PRICHARD SS, SNIDERMANN SD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286-290, 1989
9. COLLINS AJ, LI S, MA JZ, HERZOG C: Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 38:S26-29, 2001
10. SATO A, FUNDER JW, SARUTA T: Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 12:867-873, 1999
11. HOSTETTER TH, ROSENBERG ME, IBRAHIM HN, JUKNEVICIUS I: Aldosterone in renal disease. Curr Opin Nephrol Hypertens 10:105-110, 2001
12. EPSTEIN M: Aldosterone as a mediator of progressive renal dysfunction: Evolving perspectives. Intern Med 40:573-583, 2001
13. PITT B, ZANNAD F, REMME WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 34:709-717, 1999
14. SCHEPKENS H, VANHOLDER R, BILLIOUW JM, LAMEIRE N: Life-threatening hyperkalaemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 110:438-441, 2001
15. KNOLL GA, SAHGAL A, NAIR RC, et al: Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 112:110-114, 2002
16. AHMED J, WEISBERG LS: Hyperkalemia in dialysis patients. Semin Dial 14:348-356, 2001
17. ALVO M, KRSULOVIC P, FERNANDEZ V, et al: Effect of a simultaneous potassium and carbohydrate load on extrarenal K homeostasis in end-stage renal failure. Nephron 53:133-137, 1989
18. KAHN T, KAJI DM, NICOLIS G, et al: Factors related to potassium transport in chronic stable renal disease in man. Clin Sci Mol Med 54:661-666, 1978
19. PEREZ GO, PELLEYA R, OSTER JR, et al: Blunted kaliuresis after an acute potassium load in patients with chronic renal failure. Kidney Int 24:656-662, 1983
20. FERNANDEZ J, OSTER JR, PEREZ GO: Impaired extrarenal disposal of an acute oral potassium load in patients with endstage renal disease on chronic hemodialysis. Miner Electrolyte Metab 12:125-129, 1986
21. GOECKE IA, BONILLA S, MARUSlC ET, ALVO M: Enhanced insulin sensitivity in extrarenal potassium handling in uremic rats. Kidney Int 39:39-43, 1991
22. STUDER A, ZARUBA K, GRIMM J, et al: Control of plasma aldosterone during chronic hemodialysis. Clin Nephrol 13:172-176, 1980
23. SUGARMAN A, BROWN RS: The role of aldosterone in potassium tolerance: Studies in anephric humans. Kidney Int 34:397-403, 1988
24. VLASSOPOULOS D, SONIKIAN M, DARDIOTI V, et al: Insulin and mineralocorticoids influence on extrarenal potassium metabolism in chronic hemodialysis patients. Ren Fail 23:833-842, 2001
25. SAUDAN P, MACH F, PERNEGER T, et al: Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 18:2359-2363, 2003
26. HUSSAIN S, DREYFUS DE, MARCUS RJ, et al: Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 18:2364-2368, 2003
27. SICA DA, GEHR TW, YANCY C: Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. Congest Heart Fail 9:224-229, 2003
28. BEERMANN B: Aspects on pharmacokinetics of some diuretics. Acta Pharmacol Toxicol (Copenh) 54:17-29, 1984
29. STERNS RH, COX M, FEIG PU, SINGER I: Internal potassium balance and the control of the plasma potassium concentration. Medicine (Baltimore) 60:339-354, 1981
30. MARTIN RS, PANESE S, VIRGINILLO M, et al: Increased secretion of potassium in the rectum of humans with chronic renal failure. Am J Kidney Dis 8:105-110, 1986
31. HATCH M, FREEL RW, VAZIRI ND: Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure. Am J Physiol 274:F275-282, 1998
32. HAYES CP JR., MCLEOD ME, ROBINSON RR: An extravenal mechanism for the maintenance of potassium balance in severe chronic renal failure. Trans Assoc Am Physicians 80:207-216, 1967
33. SANDLE GI, GAIGER E, TAPSTER S, GOODSHIP TH: Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci (Lond) 73:247-252, 1987
34. HAYSLETT JP, BINDER HJ: Mechanism of potassium adaptation. Am J Physiol 243:F103-112, 1982
35. WEIDMANN P, MAXWELL MH, LUPU AN: Plasma aldosterone in terminal renal failure. Ann Intern Med 78:13-18, 1973
36. OLGAARD K, MADSEN S: Regulation of plasma aldosterone in anephric and non-nephrectomized patients during hemodialysis treatment. Acta Med Scand 201:457-462, 1977
37. IBRAHIM HN, HOSTETTER TH: Aldosterone in renal disease. Curr Opin Nephrol Hypertens 12:159-164, 2003
38. MARCZEWSKI K, JANICKA L, CUDNY J: The effect of pilocarpine on electrodermal resistance in chronic hemodialyzed patients. Clin Nephrol 39:88-91, 1993
39. YOSIPOVITCH G, REIS J, TUR E, et al: Sweat secretion, stratum corneum hydration, small nerve function and pruritus in patients with advanced chronic renal failure. Br J Dermatol 133:561-564, 1995
40. EARLBAUM AM, QUINTON PM: Elevated divalent ion concentrations in parotid saliva from chronic renal failure patients. Nephron 28:58-61, 1981
41. YOSIPOVITCH G, REIS J, TUR E, et al: Sweat electrolytes in patients with advanced renal failure. J Lab Clin Med 124:808-812, 1994
42. + transport regulation in distal kidney nephron cells. Cell Physiol Biochem 13:21-28, 2003
43. SNYDER PM: The epithelial Na+ channel: Cell surface insertion and retrieval in Na+ homeostasis and hypertension. Endocr Rev 23:258-275, 2002
44. MICHEA L, VALENZUELA V, BRAVO I, et al: Adrenal-dependent modulation of the catalytic subunit isoforms of the Na+-K+-ATPase in aorta. Am J Physiol 275:E1072-1081, 1998
45. AHOKAS RA, WARRINGTON KJ, GERLING IC, et al: Aldosteronism and peripheral blood mononuclear cell activation: A neuroendocrine-immune interface. Circ Res 93:124-135, 2003
46. BUBIEN JK, WATSON B, KHAN MA, et al: Expression and regulation of normal and polymorphic epithelial sodium channel by human lymphocytes. J Biol Chem 276:8557-8566, 2001
47. AHUJA TS, FREEMAN D, JR., MAHNKEN JD, et al: Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 20:268-272, 2000
48. SCHEPKENS H, VANHOLDER R, BILLIOUW JM, et al: Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 110:438-441, 2001
49. KNOLL GA, SAHGAL A, NAIR RC, et al: Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 112:110-114, 2002
50. KEILANI T, DANESH FR, SCHLUETER WA, et al: A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 33:450-457, 1999
51. TEXTOR SC: Managing renal arterial disease and hypertension. Curr Opin Cardiol 18:260-267, 2003
52. MANGRUM AJ, BAKRIS GL: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: Safety issues. Semin Nephrol 24:168-175, 2004
53. MICHEA LF, ALVO M, MORALES H, et al: Comparison of extra renal potassium management in hypertensive, diabetic and normal subjects. Rev Med Chil 125:1292-1298, 1997